Cita APA

Fung, S., Pan, C. Q., Wong, G. L., Seto, W., Ahn, S., Chen, C., & Buti Ferret, M. (2024). Atherosclerotic cardiovascular disease risk profile of patients with chronic hepatitis B treated with tenofovir alafenamide or tenofovir disoproxil fumarate for 96 weeks.

Citación estilo Chicago

Fung, Scott, Calvin Q. Pan, Grace Lai-Hung Wong, Wai-Kay Seto, Sang-Hoon Ahn, Chi-Yi Chen, y Maria Buti Ferret. Atherosclerotic Cardiovascular Disease Risk Profile of Patients With Chronic Hepatitis B Treated With Tenofovir Alafenamide or Tenofovir Disoproxil Fumarate for 96 weeks. 2024.

Cita MLA

Fung, Scott, et al. Atherosclerotic Cardiovascular Disease Risk Profile of Patients With Chronic Hepatitis B Treated With Tenofovir Alafenamide or Tenofovir Disoproxil Fumarate for 96 weeks. 2024.